Search results
28 sie 2024 · Bisphosphonates are often the first choice for osteoporosis treatment. These include: Alendronate (Fosamax), a weekly pill. Risedronate (Actonel, Atelvia), a weekly or monthly pill. Ibandronate, a monthly pill or quarterly intravenous (IV) infusion. Zoledronic acid (Reclast), an annual IV infusion.
- Osteoporosis Treatment
Mayo Clinic Press. تحقق من هذه الكتب الأكثر مبيعًا والعروض...
- Diagnosis and Treatment
This is the newest bone-building medicine to treat...
- Osteoporosis Treatment
24 lut 2024 · This is the newest bone-building medicine to treat osteoporosis. It is given as an injection every month at your doctor's office and is limited to one year of treatment. After you stop taking any of these bone-building medications, you generally will need to take another osteoporosis drug to maintain the new bone growth.
Collectively, these data establish a causal role for senescent cells in bone loss with aging, and reveal a novel therapeutic strategy to treat osteoporosis."
13 paź 2017 · In recent years, the drug denosumab (Prolia) has emerged as an alternative to bisphosphonates for the treatment of postmenopausal osteoporosis. Denosumab may be considered a first-line treatment for women with osteoporosis who are at high risk of fracture or in women who can’t take bisphosphonates.
Both nonpharmacological therapy (calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention) and pharmacological treatments (antiresorptive and anabolic agents) may be helpful in the prevention and treatment of osteoporosis.
Displaying 6 studies. The purpose of this study is to update our online decision aid for the treatment of osteoporosis to incorporate new treatment options and to prototype and field test the updated decision aid within the Bone Clinic (Endocrinology) and primary care clinics at Mayo Clinic.
In this brief review, we outline the use of the currently available medications for the management of osteoporosis—namely, estrogen, calcitonin, calcium, and vitamin D. In addition, we discuss the next generation of drugs that are likely to become available in the future—the bisphosphonates and estrogen analogues.
